Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years

Eur Urol. 2015 Feb;67(2):299-309. doi: 10.1016/j.eururo.2014.02.011. Epub 2014 Feb 18.

Abstract

Background: Prostate cancer (PCa) patients with lymph node recurrence after radical prostatectomy (RP) are usually managed with androgen-deprivation therapy. Despite the absence of prospective randomized studies, salvage lymph node dissection (LND) has been proposed as an alternative treatment option.

Objective: To examine long-term outcomes of salvage LND in patients with nodal recurrent PCa documented by 11C-choline positron emission tomography/computed tomography (PET/CT) scan.

Design, setting, and participants: Overall, 59 patients affected by biochemical recurrence (BCR) with 11C-choline PET/CT scan with pathologic activity treated between 2002 and 2008 were included.

Intervention: Pelvic and/or retroperitoneal salvage LND.

Outcome measurements and statistical analyses: Biochemical response (BR) was defined as prostate-specific antigen (PSA) <0.2 ng/ml at 40 d after surgery. BCR for those who achieved BR was defined as a PSA >0.2 ng/ml. Clinical recurrence (CR) was defined as a positive PET/CT scan after salvage LND in the presence of a rising PSA. Kaplan-Meier curves assessed time to BCR, CR, and cancer-specific mortality (CSM). Cox regression analyses were fitted to assess predictors of CR.

Results and limitations: Median follow-up after salvage LND was 81.1 mo. Overall, 35 patients (59.3%) achieved BR. The 8-yr BCR-free survival rate in patients with complete BR was 23%. Overall, the 8-yr CR- and CSM-free survival rates were 38% and 81%, respectively. In multivariable analyses evaluating preoperative variables, PSA at salvage LND represented the only predictor of CR (p=0.03). When postoperative variables were considered, BR and the presence of retroperitoneal lymph node metastases were significantly associated with the risk of CR (all p ≤ 0.04). Our study is limited by the lack of a control group.

Conclusions: Salvage LND may represent a therapeutic option for patients with BCR after RP and nodal pathologic uptake at 11C-choline PET/CT scan. Although most patients progressed to BCR after salvage LND, roughly 40% of them experienced CR-free survival.

Patient summary: Salvage lymph node dissection may represent a therapeutic option for selected patients with nodal recurrence after radical prostatectomy. Roughly 40% of men did not show any further clinical recurrence at long-term follow-up after surgery.

Keywords: Cancer-specific mortality; Clinical recurrence; Lymph node metastases; Prostate cancer; Salvage lymph node dissection.

MeSH terms

  • Aged
  • Biomarkers / blood
  • Disease-Free Survival
  • Humans
  • Italy
  • Kallikreins / blood
  • Kaplan-Meier Estimate
  • Lymph Node Excision / adverse effects
  • Lymph Node Excision / methods*
  • Lymph Node Excision / mortality
  • Lymph Nodes / diagnostic imaging
  • Lymph Nodes / pathology
  • Lymph Nodes / surgery*
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Multimodal Imaging
  • Multivariate Analysis
  • Positron-Emission Tomography
  • Predictive Value of Tests
  • Proportional Hazards Models
  • Prostate-Specific Antigen / blood
  • Prostatectomy* / adverse effects
  • Prostatectomy* / mortality
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / surgery*
  • Reoperation
  • Risk Factors
  • Salvage Therapy / adverse effects
  • Salvage Therapy / methods*
  • Salvage Therapy / mortality
  • Time Factors
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Biomarkers
  • KLK3 protein, human
  • Kallikreins
  • Prostate-Specific Antigen